HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buggins, A. G. S. Articles by Hirst, W. J. R. Search for Related Content PubMed PubMed Citation Articles by Buggins, A. G. S. Articles by Hirst, W. J. R.

Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-B, c-Myc, and pRb Pathways

Department of Haematological Medicine, Leukaemia Sciences, Guy’s, King’s and St. Thomas’ School of Medicine, Rayne Institute, London, United Kingdom

Tumors produce a variety of immunosuppressive factors which can prevent the proliferation and maturation of a number of normal hemopoietic cell types. We have investigated whether primary acute myeloid leukemia (AML) cells have an effect on normal T cell function and signaling. Tumor cell supernatant (TSN) from AML cells inhibited T cell activation and Th1 cytokine production and also prevented activated T cells from entering the cell cycle. These effects occurred in the absence of AML cell-T cell contact. We have demonstrated that AML TSN contained none of the immunosuppressors described to date, namely gangliosides, nitric oxide, TGF-, IL-10, vascular endothelial growth factor, or PGs. Furthermore, IL-2 did not overcome the block, despite normal IL-2R expression. However, the effect was overcome by preincubation with inhibitors of protein secretion and abolished by trypsinization, indicating that the active substance includes one or more proteins. To determine the mechanism of inhibition, we have studied many of the major pathways involved in T cell activation and proliferation. We show that nuclear translocation of NFATc and NF-B are markedly reduced in T cells activated in the presence of primary AML cells. In contrast, calcium mobilization and activation of other signal transduction pathways, namely extracellular signal-regulated kinase1/2, p38, and STAT5 were unaffected, but activation of c-Jun N-terminal kinase 1/2 was delayed. Phosphorylation of pRb by cyclin-dependent kinase 6/4-cyclin D and of p130 did not occur and c-Myc, cyclin D3, and p107 were not induced, consistent with cell cycle inhibition early during the transition from G₀ to G₁. Our data indicate that TSN generated by AML cells induces T cell immunosuppression and provides a mechanism by which the leukemic clone could evade T cell-mediated killing.

This article has been cited by other articles:

				R. Le Dieu, D. C. Taussig, A. G. Ramsay, R. Mitter, F. Miraki-Moud, R. Fatah, A. M. Lee, T. A. Lister, and J. G. Gribben Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts Blood, October 29, 2009; 114(18): 3909 - 3916. [Abstract] [Full Text] [PDF]

				A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology Blood, March 12, 2009; 113(11): 2394 - 2401. [Abstract] [Full Text] [PDF]

				A. Curti, S. Pandolfi, B. Valzasina, M. Aluigi, A. Isidori, E. Ferri, V. Salvestrini, G. Bonanno, S. Rutella, I. Durelli, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells Blood, April 1, 2007; 109(7): 2871 - 2877. [Abstract] [Full Text] [PDF]

				M. Brune, S. Castaigne, J. Catalano, K. Gehlsen, A. D. Ho, W.-K. Hofmann, D. E. Hogge, B. Nilsson, R. Or, A. I. Romero, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood, July 1, 2006; 108(1): 88 - 96. [Abstract] [Full Text] [PDF]

				C. Liu, S. Yu, K. Zinn, J. Wang, L. Zhang, Y. Jia, J. C. Kappes, S. Barnes, R. P. Kimberly, W. E. Grizzle, et al. Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function J. Immunol., February 1, 2006; 176(3): 1375 - 1385. [Abstract] [Full Text] [PDF]

				D. Milojkovic, S. Devereux, N. B. Westwood, G. J. Mufti, N. S. B. Thomas, and A. G. S. Buggins Antiapoptotic Microenvironment of Acute Myeloid Leukemia J. Immunol., December 1, 2004; 173(11): 6745 - 6752. [Abstract] [Full Text] [PDF]

				M. V. Thornton, D. Kudo, P. Rayman, C. Horton, L. Molto, M. K. Cathcart, C. Ng, E. Paszkiewicz-Kozik, R. Bukowski, I. Derweesh, et al. Degradation of NF-{kappa}B in T Cells by Gangliosides Expressed on Renal Cell Carcinomas J. Immunol., March 15, 2004; 172(6): 3480 - 3490. [Abstract] [Full Text] [PDF]

				N. C. Lea, S. J. Orr, K. Stoeber, G. H. Williams, E. W.-F. Lam, M. A. A. Ibrahim, G. J. Mufti, and N. S. B. Thomas Commitment Point during G0->G1 That Controls Entry into the Cell Cycle Mol. Cell. Biol., April 1, 2003; 23(7): 2351 - 2361. [Abstract] [Full Text] [PDF]